Market closed

Mirum Pharmaceuticals/$MIRM

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Mirum Pharmaceuticals

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Ticker

$MIRM
Trading on

Industry

Biotechnology

Employees

311

MIRM Metrics

BasicAdvanced
$2.1B
Market cap
-
P/E ratio
-$2.12
EPS
1.16
Beta
-
Dividend rate
$2.1B
1.16
$45.23
$23.14
359K
3.34
3.049
136.256
136.905
-6.71%
-9.10%
-39.84%
6.868
9.25
-90.27
-77.532
112.14%
-50.55%
167.72%
-29.77%

What the Analysts think about MIRM

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Mirum Pharmaceuticals stock.

MIRM Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MIRM Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MIRM

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Mirum Pharmaceuticals stock?

Mirum Pharmaceuticals (MIRM) has a market cap of $2.1B as of November 24, 2024.

What is the P/E ratio for Mirum Pharmaceuticals stock?

The price to earnings (P/E) ratio for Mirum Pharmaceuticals (MIRM) stock is 0 as of November 24, 2024.

Does Mirum Pharmaceuticals stock pay dividends?

No, Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders as of November 24, 2024.

When is the next Mirum Pharmaceuticals dividend payment date?

Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders.

What is the beta indicator for Mirum Pharmaceuticals?

Mirum Pharmaceuticals (MIRM) has a beta rating of 1.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.